Ranking by Regions
United States
Canada
Mexico
Brazil
Chile
Germany
United Kingdom
France
Spain
Netherlands
Sweden
Italy
Switzerland
Poland
Finland
China
Japan
South Korea
Hong Kong
Singapore
Indonesia
India
Malaysia
Taiwan
Thailand
Australia
New Zealand
Israel
Saudi Arabia
Turkey
Russia
South AfricaRanking by categories
As of January 22, 2025, Novo Nordisk (NVO) has a market cap of $339.94 billion USD. According to our data, Novo Nordisk is ranked No.29 in global market value.
| Year | Market Cap | %Change |
|---|---|---|
| Jan 22, 2025 | $339.94 B |
17.43%
|
| Dec 31, 2024 | $289.48 B |
-15.94%
|
| Dec 29, 2023 | $344.36 B |
54.84%
|
| Dec 30, 2022 | $222.39 B |
22.66%
|
| Dec 31, 2021 | $181.31 B |
63.52%
|
| Dec 31, 2020 | $110.88 B |
21.62%
|
| Dec 31, 2019 | $91.17 B |
28.70%
|
| Dec 31, 2018 | $70.84 B |
-12.12%
|
| Dec 29, 2017 | $80.60 B |
54.23%
|
| Dec 30, 2016 | $52.26 B |
-36.56%
|
| Dec 31, 2015 | $82.39 B |
39.39%
|
| Dec 31, 2014 | $59.11 B |
16.67%
|
| Dec 31, 2013 | $50.66 B |
15.41%
|
| Dec 31, 2012 | $43.90 B |
44.09%
|
| Dec 30, 2011 | $30.47 B |
3.91%
|
| Dec 31, 2010 | $29.32 B |
79.50%
|
| Dec 31, 2009 | $16.33 B |
26.98%
|
| Dec 31, 2008 | $12.86 B |
-19.73%
|
| Dec 31, 2007 | $16.02 B |
57.38%
|
| Dec 29, 2006 | $10.18 B |
51.05%
|
| Dec 30, 2005 | $6.74 B |
5.27%
|
| Dec 31, 2004 | $6.40 B |
34.63%
|
| Dec 31, 2003 | $4.76 B |
43.96%
|
| Dec 31, 2002 | $3.30 B |
-27.23%
|
| Dec 31, 2001 | $4.54 B |
14.20%
|
| Dec 29, 2000 | $3.98 B |
38.73%
|
| Dec 31, 1999 | $2.87 B |
-2.01%
|
| Dec 31, 1998 | $2.92 B |
-7.33%
|
| Dec 31, 1997 | $3.16 B |
55.13%
|
| Dec 31, 1996 | $2.03 B |
38.16%
|
| Dec 29, 1995 | $1.47 B |
45.41%
|
| Dec 30, 1994 | $1.01 B |
-3.00%
|
| Dec 31, 1993 | $1.04 B |
12.22%
|
| Dec 31, 1992 | $0.93 B |
-0.12%
|
| Dec 31, 1991 | $0.93 B |
44.61%
|
| Dec 31, 1990 | $0.64 B |
26.19%
|
| Dec 29, 1989 | $0.51 B |
30.77%
|
| Dec 30, 1988 | $0.39 B |
84.64%
|
| Dec 31, 1987 | $0.21 B |
-34.25%
|
| Dec 31, 1986 | $0.32 B |
13.04%
|
| Dec 31, 1985 | $0.28 B |
24.90%
|
| Dec 31, 1984 | $0.23 B |
-57.33%
|
| Dec 30, 1983 | $0.53 B |
28.31%
|
| Dec 31, 1982 | $0.42 B |
10.19%
|
| Dec 31, 1981 | $0.38 B |
100%
|
| Name | Market Cap | Market cap difference | Regions |
|---|---|---|---|
 Eli Lilly
LLY
|
$679.60 B |
0.019 M
|
USA
|
 Sanofi
SNY
|
$129.28 B |
-0.313 B
|
France
|
 Pfizer
PFE
|
$149.69 B |
-1.275 B
|
USA
|
 Merck
MRK
|
$242.90 B |
-0.007 M
|
USA
|
 AstraZeneca
AZN
|
$211.74 B |
0.000 M
|
UK
|
 GlaxoSmithKline
GSK
|
$68.73 B |
-0.194 B
|
UK
|
 Johnson & Johnson
JNJ
|
$344.66 B |
0.016 M
|
USA
|
 Bristol-Myers Squibb
BMY
|
$114.88 B |
-0.811 B
|
USA
|
 Amgen
AMGN
|
$147.39 B |
-0.333 B
|
USA
|
 AbbVie
ABBV
|
$298.08 B |
-0.039 B
|
USA
|
 Novartis
NVS
|
$197.85 B |
0.002 M
|
Switzerland
|
 Takeda Pharmaceutical
TAK
|
$41.29 B |
-0.238 B
|
Japan
|
 Biogen
BIIB
|
$20.75 B |
0.203 B
|
USA
|
| Market Cap | = | NVO Stock Price | * | NVO Shares Outstanding |
| = | $81.70 | * | 3.37 B | |
| = | $339.94 B |